N-((1R,3S,4S)-3-((4-(3-benzyl-1-ethyl-1H-pyrazol-5-yl)piperidin-1-yl)methyl)-4-(3-fluorophenyl)cyclopentyl)-N-methyl-D-valine

Catalog No. :
ACALIJ754
CAS No. :
313994-79-5
Molecular Formula :
C35H47FN4O2
Molecular Weight :
574.78

IUPAC Name:N-((1R,3S,4S)-3-((4-(3-benzyl-1-ethyl-1H-pyrazol-5-yl)piperidin-1-yl)methyl)-4-(3-fluorophenyl)cyclopentyl)-N-methyl-D-valine

N-((1R,3S,4S)-3-((4-(3-benzyl-1-ethyl-1H-pyrazol-5-yl)piperidin-1-yl)methyl)-4-(3-fluorophenyl)cyclopentyl)-N-methyl-D-valine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-((1R,3S,4S)-3-((4-(3-benzyl-1-ethyl-1H-pyrazol-5-yl)piperidin-1-yl)methyl)-4-(3-fluorophenyl)cyclopentyl)-N-methyl-D-valine
IUPAC NameN-((1R,3S,4S)-3-((4-(3-benzyl-1-ethyl-1H-pyrazol-5-yl)piperidin-1-yl)methyl)-4-(3-fluorophenyl)cyclopentyl)-N-methyl-D-valine
Molecular FormulaC35H47FN4O2
Molecular Weight574.78
SMILESCCN1N=C(CC2=CC=CC=C2)C=C1C1CCN(C[C@H]2C[C@H](N(C)[C@@H](C(=O)O)C(C)C)C[C@@H]2C2=CC=CC(F)=C2)CC1
InChI KeyZTENZJJCFACIAK-ADWVOTLJSA-N
SynonymTox21_300223 | DTXCID8027327 | MK-578 | Q27087736 | CAS-313994-79-5 | (2R)-2-[[(1R,3S,4S)-3-[[4-(5-benzyl-2-ethyl-pyrazol-3-yl)-1-piperidyl]methyl]-4-(3-fluorophenyl)cyclopentyl]-methyl-amino]-3-methyl-butanoic acid | (2R)-2-[[(1R,3S,4S)-3-[[4-[2-ethyl-5-
CAS No.313994-79-5
PubChem CID5481119

Synthetic Route by SureRoute

1. ACALIJ754 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACALIJ754 route product structure diagram
    ACALIJ754313994-79-5
Inquiry

2. ACALIJ754 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACALIJ754 route product structure diagram
    ACALIJ754313994-79-5
Inquiry

Comments (0)